Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
Pharmacogenomics|November 3, 2017
An assessment of the impact of pharmacogenomics on health disparities: a systematic literature reviewAntony Martin, Jennifer Downing, Michelle Maden, et al.
Health Technology Assessment (Winchester, England)|June 29, 2026
Digital front door technologies to pre-assess people before assessment for NHS Talking Therapies [HTE10055]: early value assessmentNigel Fleeman, James Mahon, Samuel Bryning, et al.
The Cochrane Database of Systematic Reviews|February 17, 2012
Deferasirox for managing iron overload in people with thalassaemiaJoerg J Meerpohl, Gerd Antes, Gerta Rücker, et al.
The Cochrane Database of Systematic Reviews|November 12, 2010
Deferasirox for managing iron overload in people with myelodysplastic syndromeJoerg J Meerpohl, Gerd Antes, Gerta Rücker, et al.
Health Technology Assessment (Winchester, England)|October 29, 2015
The clinical effectiveness and cost-effectiveness of the PROGENSA® prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluationAmanda Nicholson, James Mahon, Angela Boland, et al.
The Cochrane Database of Systematic Reviews|October 29, 2014
Deferasirox for managing iron overload in people with myelodysplastic syndromeJoerg J Meerpohl, Lisa K Schell, Gerta Rücker, et al.
The Cochrane Database of Systematic Reviews|June 4, 2014
Deferasirox for managing transfusional iron overload in people with sickle cell diseaseJoerg J Meerpohl, Lisa K Schell, Gerta Rücker, et al.
Pharmacoeconomics - Open|March 25, 2020
Brentuximab Vedotin for Treating Relapsed or Refractory CD30-Positive Cutaneous T-Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology AppraisalAngela Stainthorpe, Nigel Fleeman, Rachel Houten, et al.
BMC Cancer|December 14, 2019
A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodineNigel Fleeman, Rachel Houten, Marty Chaplin, et al.
Pharmacoeconomics|May 15, 2010
Cetuximab for recurrent and/or metastatic squamous cell carcinoma of the head and neck: a NICE single technology appraisalAdrian Bagust, Janette Greenhalgh, Angela Boland, et al.
Pageof 4